New Insights into the Anticancer Effects and Toxicogenomic Safety of Two β-Lapachone Derivatives.

IF 4.3 3区 医学 Q2 CHEMISTRY, MEDICINAL
Pharmaceuticals Pub Date : 2025-06-03 DOI:10.3390/ph18060837
José Rivaldo De Lima, Alexandre José Da Silva Góes, Elizabeth Fernanda De Oliveira Borba, Meykson Alexandre da Silva, Rodrigo Ribeiro Alves Caiana, Maria do Desterro Rodrigues, Mariza Severina De Lima Silva, Cristiano Aparecido Chagas, Blandine Baratte, Thomas Robert, Stéphane Bach, Isabelle Ourliac-Garnier, Pascal Marchand, Teresinha Gonçalves Da Silva
{"title":"New Insights into the Anticancer Effects and Toxicogenomic Safety of Two β-Lapachone Derivatives.","authors":"José Rivaldo De Lima, Alexandre José Da Silva Góes, Elizabeth Fernanda De Oliveira Borba, Meykson Alexandre da Silva, Rodrigo Ribeiro Alves Caiana, Maria do Desterro Rodrigues, Mariza Severina De Lima Silva, Cristiano Aparecido Chagas, Blandine Baratte, Thomas Robert, Stéphane Bach, Isabelle Ourliac-Garnier, Pascal Marchand, Teresinha Gonçalves Da Silva","doi":"10.3390/ph18060837","DOIUrl":null,"url":null,"abstract":"<p><p><b>Background/Objectives:</b> β-Lapachone (β-lap) is an <i>o</i>-naphthoquinone with potent antitumor activity. However, its clinical application is hindered by poor solubility and toxicity. Thiosemicarbazone derivatives of β-lap (BV3 and BV5) have demonstrated enhanced selectivity and anticancer efficacy in leukemia cells. Therefore, this study aimed to evaluate the therapeutic potential of these derivatives in solid tumors. Furthermore, the mechanism of tumor cell death, the involvement of protein kinase inhibition, and the toxicogenetic safety of BV3 and BV5 were investigated. <b>Methods</b>: The cytotoxic effects of BV3 and BV5 were assessed in cancer cell lines and a non-cancerous cell line. The compounds were most effective against HeLa (human cervical adenocarcinoma) cells. For that reason, this type of cell was chosen to study how the compounds might cause cell death, using flow cytometry. Kinase inhibition assays were conducted in vitro and in silico, followed by genotoxicity assessments to determine toxicogenetic safety. <b>Results</b>: BV3 and BV5 derivatives significantly inhibited cancer cell proliferation after 72 h, with IC<sub>50</sub> values ranging from 2.8 to 36.9 µM. BV3 demonstrated superior selectivity (selectivity index: 15.6) when compared to β-lap (selectivity index: 1.9) in HeLa cells. Morphological changes and flow cytometry analysis revealed features of apoptosis and/or necrosis in HeLa cells treated with the compounds BV3 and BV5. Furthermore, among the kinases tested, BV3 and BV5 were more effective in inhibiting the activity of the protein kinases JAK3 and GSK3β. This result was also confirmed by the in silico studies. Additionally, genotoxicity assays indicated an overall favorable toxicogenetic safety profile; however, BV5 exhibited potential genotoxicity at high concentrations. <b>Conclusions</b>: The findings underscore the anticancer potential of BV3 and BV5 in solid tumors and highlight their mechanism of action, which involves protein kinases. The findings also show that the drugs are selective and relatively safe.</p>","PeriodicalId":20198,"journal":{"name":"Pharmaceuticals","volume":"18 6","pages":""},"PeriodicalIF":4.3000,"publicationDate":"2025-06-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12196213/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmaceuticals","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3390/ph18060837","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
引用次数: 0

Abstract

Background/Objectives: β-Lapachone (β-lap) is an o-naphthoquinone with potent antitumor activity. However, its clinical application is hindered by poor solubility and toxicity. Thiosemicarbazone derivatives of β-lap (BV3 and BV5) have demonstrated enhanced selectivity and anticancer efficacy in leukemia cells. Therefore, this study aimed to evaluate the therapeutic potential of these derivatives in solid tumors. Furthermore, the mechanism of tumor cell death, the involvement of protein kinase inhibition, and the toxicogenetic safety of BV3 and BV5 were investigated. Methods: The cytotoxic effects of BV3 and BV5 were assessed in cancer cell lines and a non-cancerous cell line. The compounds were most effective against HeLa (human cervical adenocarcinoma) cells. For that reason, this type of cell was chosen to study how the compounds might cause cell death, using flow cytometry. Kinase inhibition assays were conducted in vitro and in silico, followed by genotoxicity assessments to determine toxicogenetic safety. Results: BV3 and BV5 derivatives significantly inhibited cancer cell proliferation after 72 h, with IC50 values ranging from 2.8 to 36.9 µM. BV3 demonstrated superior selectivity (selectivity index: 15.6) when compared to β-lap (selectivity index: 1.9) in HeLa cells. Morphological changes and flow cytometry analysis revealed features of apoptosis and/or necrosis in HeLa cells treated with the compounds BV3 and BV5. Furthermore, among the kinases tested, BV3 and BV5 were more effective in inhibiting the activity of the protein kinases JAK3 and GSK3β. This result was also confirmed by the in silico studies. Additionally, genotoxicity assays indicated an overall favorable toxicogenetic safety profile; however, BV5 exhibited potential genotoxicity at high concentrations. Conclusions: The findings underscore the anticancer potential of BV3 and BV5 in solid tumors and highlight their mechanism of action, which involves protein kinases. The findings also show that the drugs are selective and relatively safe.

两种β-Lapachone衍生物抗癌作用及毒理学安全性的新认识。
背景/目的:β-Lapachone (β-lap)是一种具有抗肿瘤活性的邻萘醌类化合物。但其溶解度和毒性较差,阻碍了其临床应用。β-lap的硫代氨基脲衍生物(BV3和BV5)在白血病细胞中显示出增强的选择性和抗癌作用。因此,本研究旨在评估这些衍生物在实体肿瘤中的治疗潜力。此外,还对BV3和BV5的肿瘤细胞死亡机制、参与的蛋白激酶抑制以及毒理学安全性进行了研究。方法:观察BV3和BV5对癌细胞和非癌细胞的细胞毒作用。这些化合物对人宫颈腺癌(HeLa)细胞最有效。因此,选择这种类型的细胞来研究化合物如何导致细胞死亡,使用流式细胞术。在体外和计算机上进行了激酶抑制试验,随后进行了遗传毒性评估以确定毒理学安全性。结果:BV3和BV5衍生物在72h后显著抑制癌细胞增殖,IC50值为2.8 ~ 36.9µM。与β-lap(选择性指数:1.9)相比,BV3在HeLa细胞中表现出更高的选择性(选择性指数:15.6)。形态学变化和流式细胞术分析显示化合物BV3和BV5处理HeLa细胞具有凋亡和/或坏死的特征。此外,在测试的激酶中,BV3和BV5对JAK3和GSK3β蛋白激酶的活性抑制更有效。这一结果也得到了计算机研究的证实。此外,遗传毒性试验表明总体有利的毒理学安全性;然而,BV5在高浓度时表现出潜在的遗传毒性。结论:这些发现强调了BV3和BV5在实体肿瘤中的抗癌潜力,并强调了它们的作用机制,其作用机制涉及蛋白激酶。研究结果还表明,这些药物具有选择性,而且相对安全。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Pharmaceuticals
Pharmaceuticals Pharmacology, Toxicology and Pharmaceutics-Pharmaceutical Science
CiteScore
6.10
自引率
4.30%
发文量
1332
审稿时长
6 weeks
期刊介绍: Pharmaceuticals (ISSN 1424-8247) is an international scientific journal of medicinal chemistry and related drug sciences.Our aim is to publish updated reviews as well as research articles with comprehensive theoretical and experimental details. Short communications are also accepted; therefore, there is no restriction on the maximum length of the papers.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信